angiogenesis inhibitors

Summary

Summary: Agents and endogenous substances that antagonize or inhibit the development of new blood vessels.

Top Publications

  1. ncbi Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
  2. ncbi Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Science 307:58-62. 2005
  3. pmc Modes of resistance to anti-angiogenic therapy
    Gabriele Bergers
    University of California, San Francisco, Department of Neurological Surgery, Brain Tumour Research Center, San Francisco, California 94143, USA
    Nat Rev Cancer 8:592-603. 2008
  4. pmc Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    Marta Pàez-Ribes
    Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L Hospitalet de Llobregat, Spain
    Cancer Cell 15:220-31. 2009
  5. ncbi Ranibizumab for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    N Engl J Med 355:1419-31. 2006
  6. doi Tumor angiogenesis
    Robert S Kerbel
    Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto, Toronto
    N Engl J Med 358:2039-49. 2008
  7. ncbi Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007
  8. ncbi Role of angiogenesis in tumor growth and metastasis
    Judah Folkman
    Departments of Surgery and Cell Biology, Harvard Medical School, Boston, MA, USA
    Semin Oncol 29:15-8. 2002
  9. pmc Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results
    Daniel F Martin
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Ophthalmology 119:1388-98. 2012
  10. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009

Detail Information

Publications311 found, 100 shown here

  1. ncbi Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    Alan Sandler
    Vanderbilt University, Nashville, TN, USA
    N Engl J Med 355:2542-50. 2006
    ..Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers...
  2. ncbi Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy
    Rakesh K Jain
    E L Steele Lab for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital, and Harvard Medical School, COX 7, 100 Blossom Street, Boston, MA 02114, USA
    Science 307:58-62. 2005
    ....
  3. pmc Modes of resistance to anti-angiogenic therapy
    Gabriele Bergers
    University of California, San Francisco, Department of Neurological Surgery, Brain Tumour Research Center, San Francisco, California 94143, USA
    Nat Rev Cancer 8:592-603. 2008
    b>Angiogenesis inhibitors targeting the vascular endothelial growth factor (VEGF) signalling pathways are affording demonstrable therapeutic efficacy in mouse models of cancer and in an increasing number of human cancers...
  4. pmc Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis
    Marta Pàez-Ribes
    Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L Hospitalet de Llobregat, Spain
    Cancer Cell 15:220-31. 2009
    Multiple angiogenesis inhibitors have been therapeutically validated in preclinical cancer models, and several in clinical trials...
  5. ncbi Ranibizumab for neovascular age-related macular degeneration
    Philip J Rosenfeld
    Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    N Engl J Med 355:1419-31. 2006
    ..Ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--has been evaluated for the treatment of neovascular age-related macular degeneration...
  6. doi Tumor angiogenesis
    Robert S Kerbel
    Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, and the Department of Medical Biophysics, University of Toronto, Toronto
    N Engl J Med 358:2039-49. 2008
  7. ncbi Angiogenesis: an organizing principle for drug discovery?
    Judah Folkman
    Childrens Hospital and Harvard Medical School Boston, Massachusetts, USA
    Nat Rev Drug Discov 6:273-86. 2007
    ..This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing ..
  8. ncbi Role of angiogenesis in tumor growth and metastasis
    Judah Folkman
    Departments of Surgery and Cell Biology, Harvard Medical School, Boston, MA, USA
    Semin Oncol 29:15-8. 2002
    ..Phase 1 clinical trials of endostatin and angiostatin are ongoing, and preliminary results show minimal toxicities...
  9. pmc Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results
    Daniel F Martin
    Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio, USA
    Ophthalmology 119:1388-98. 2012
    ..To describe effects of ranibizumab and bevacizumab when administered monthly or as needed for 2 years and to describe the impact of switching to as-needed treatment after 1 year of monthly treatment...
  10. ncbi Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
    John M L Ebos
    Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada
    Cancer Cell 15:232-9. 2009
    ....
  11. ncbi Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis
    Daniel J Hicklin
    Department of Experimental Therapeutics, ImClone Systems Incorporated, New York, NY 10014, USA
    J Clin Oncol 23:1011-27. 2005
    ....
  12. ncbi Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    David M Brown
    Vitreoretinal Consultants, Methodist Hospital, Houston, TX 77030, USA
    N Engl J Med 355:1432-44. 2006
    ....
  13. ncbi Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial
    Usha Chakravarthy
    Institute of Clinical Science, The Queen s University of Belfast, Belfast, Ireland
    Ophthalmology 119:1399-411. 2012
    ..To compare the efficacy and safety of ranibizumab and bevacizumab intravitreal injections to treat neovascular age-related macular degeneration (nAMD)...
  14. ncbi Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases
    Peter Carmeliet
    Vesalius Research Center, VIB, K U Leuven, Campus Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Nat Rev Drug Discov 10:417-27. 2011
    ..Here, we discuss the mechanisms, benefits, limitations and possible clinical translation of vessel normalization for cancer and other angiogenic disorders...
  15. ncbi Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
    Napoleone Ferrara
    Department of Molecular Oncology, Genentech, Inc, 1 DNA Way, South San Francisco, California 94080, USA
    Nat Rev Drug Discov 3:391-400. 2004
  16. ncbi The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
    Paul Mitchell
    Centre for Vision Research Westmead Millennium Institute, University of Sydney, Sydney, Australia
    Ophthalmology 118:615-25. 2011
    ..To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME)...
  17. ncbi The role of myeloid cells in the promotion of tumour angiogenesis
    Craig Murdoch
    Department of Oral and Maxillofacial Surgery, School of Clinical Dentistry, Beech Hill Road, University of Sheffield, Sheffield, UK
    Nat Rev Cancer 8:618-31. 2008
    ..We also discuss the therapeutic implications of recent findings that specific myeloid cell populations modulate the responses of tumours to agents such as chemotherapy and some anti-angiogenic therapies...
  18. ncbi Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
    David M Brown
    Vitreoretinal Consultants, Methodist Hospital, Houston, Texas 77030, USA
    Ophthalmology 116:57-65.e5. 2009
    ....
  19. ncbi Angiogenesis
    Judah Folkman
    Vascular Biology Program, Children s Hospital and Harvard Medical School, Boston, Massachusetts 02115 5737, USA
    Annu Rev Med 57:1-18. 2006
    b>Angiogenesis inhibitors for the treatment of cancer have now been approved by the Food and Drug Administration in the United States, and in 28 other countries including China...
  20. pmc Integrins in angiogenesis and lymphangiogenesis
    Christie J Avraamides
    Moores UCSD Cancer Center, 3, 855 Health Sciences Drive, La Jolla, California 92092 0819, USA
    Nat Rev Cancer 8:604-17. 2008
    ..Several integrin-targeted therapeutic agents are currently in clinical trials for cancer therapy. Here, we review the evidence implicating integrins as a family of fundamental regulators of angiogenesis and lymphangiogenesis...
  21. ncbi An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration
    Anne E Fung
    Pacific Eye Associates, California Pacific Medical Center, San Francisco, California, USA
    Am J Ophthalmol 143:566-83. 2007
    ..To evaluate an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD)...
  22. pmc VEGF inhibition and renal thrombotic microangiopathy
    Vera Eremina
    Samuel Lunenfeld Research Institute, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
    N Engl J Med 358:1129-36. 2008
    ..These observations provide evidence that glomerular injury in patients who are treated with bevacizumab is probably due to direct targeting of VEGF by antiangiogenic therapy...
  23. ncbi Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis
    Vishal Ranpura
    Department of Medicine, Stony Brook University Cancer Center, 9447 SUNY, Stony Brook, NY 11794, USA
    JAMA 305:487-94. 2011
    ..Currently, the role of bevacizumab in treatment-related mortality is not clear...
  24. ncbi Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
    Stephen A Cannistra
    Beth Israel Deaconess Medical Center, East Campus KS158, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 25:5180-6. 2007
    ....
  25. pmc Mechanisms of adverse effects of anti-VEGF therapy for cancer
    T Kamba
    Department of Urology, Kyoto University, 54 Kawahara cho, Shogoin, Sakyo ku, Kyoto 606 8507, Japan
    Br J Cancer 96:1788-95. 2007
    ..These changes are generally manageable and pose less risk than the tumours being treated, but they highlight the properties shared by tumour vessels and the vasculature of normal organs...
  26. pmc Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial
    Roy S Herbst
    Department of Thoracic Head and Neck Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Lancet 377:1846-54. 2011
    ....
  27. ncbi Anti-angiogenesis therapy in cancer: current challenges and future perspectives
    Farbod Shojaei
    Oncology Research Unit, Pfizer La Jolla, CA 92121, United States
    Cancer Lett 320:130-7. 2012
    ..Investigations in clinic and preclinical models have provided some molecular and cellular mechanisms for the above challenges. This review aims to provide a concise update from recent findings...
  28. ncbi Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    N Engl J Med 356:115-24. 2007
    ..Since sunitinib malate has shown activity in two uncontrolled studies in patients with metastatic renal-cell carcinoma, a comparison of the drug with interferon alfa in a phase 3 trial is warranted...
  29. ncbi Angiogenesis as a therapeutic target
    Napoleone Ferrara
    Genentech, 1 DNA Way, South San Francisco, California 94080, USA
    Nature 438:967-74. 2005
    ..Therapeutic angiogenesis (promoting new vessel growth to treat ischaemic disorders) is an exciting frontier of cardiovascular medicine, but further understanding of the mechanisms of vascular morphogenesis is needed first...
  30. ncbi Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
    John M L Ebos
    Division of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, S 217 Research Building, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada
    Nat Rev Clin Oncol 8:210-21. 2011
    ..Improved preclinical assessment of all stages of metastatic disease should be a priority for future antiangiogenic drug discovery and development...
  31. ncbi Clinical translation of angiogenesis inhibitors
    Robert Kerbel
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, S 218, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Nat Rev Cancer 2:727-39. 2002
    b>Angiogenesis inhibitors are a new class of drugs, for which the general rules involving conventional chemotherapy might not apply...
  32. ncbi Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE)
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 26:5326-34. 2008
    ..1 months was reported. The association between various pre- and post-treatment factors (including the use of bevacizumab beyond first progression [BBP]) and survival was examined...
  33. ncbi Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials
    P Mitchell
    Eye Clinic B4A, Westmead Hospital, Hawkesbury Road, Westmead, NSW, 2145, Australia
    Br J Ophthalmol 94:2-13. 2010
    ..Ranibizumab is approved for treating neovascular AMD. However, further guidance is needed to assist ophthalmologists in clinical practice to optimise treatment outcomes...
  34. ncbi Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors
    Yuval Shaked
    Department of Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, Ontario M4N 3M5, Canada
    Science 313:1785-7. 2006
    ..These findings also provide a mechanistic rationale for the enhanced efficacy of VDAs when combined with antiangiogenic drugs...
  35. pmc Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion
    A Gregory Sorensen
    AA Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA 02129, USA
    Cancer Res 72:402-7. 2012
    ..Together, our findings offer direct clinical evidence in support of the hypothesis that vascular normalization can increase tumor perfusion and help improve patient survival...
  36. ncbi Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study
    Frank G Holz
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Ophthalmology 118:663-71. 2011
    ..To evaluate the safety and efficacy of individualized ranibizumab treatment in patients with neovascular age-related macular degeneration...
  37. ncbi Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 620
    Stefan Sleijfer
    Dept of Medical Oncology, Erasmus University Medical Center, Daniel den Hoed Cancer Center, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands
    J Clin Oncol 27:3126-32. 2009
    ..7%). CONCLUSION Pazopanib is well tolerated in patients with relapsed, advanced STS and demonstrates interesting activity that warrants additional study in patients with leiomyosarcomas, synovial sarcomas, and other STS types...
  38. ncbi Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1
    Carl D Regillo
    Retina Service, Wills Eye Institute, 840 Walnut Street, Philadelphia, PA 19107, USA
    Am J Ophthalmol 145:239-248. 2008
    ..To evaluate the efficacy and safety of ranibizumab administered monthly for three months and then quarterly in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)...
  39. ncbi A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study
    Geeta A Lalwani
    Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida 33136, USA
    Am J Ophthalmol 148:43-58.e1. 2009
    ....
  40. ncbi VEGF as a key mediator of angiogenesis in cancer
    Peter Carmeliet
    Center for Transgene Technology and Gene Therapy, Flander s Interuniversity Institute for Biotechnology, University of Leuven, Leuven, Belgium
    Oncology 69:4-10. 2005
    ..These characteristics mean that tumor blood flow is suboptimal, resulting in hypoxia and further VEGF production. This central role of VEGF in the production of tumor vasculature makes it a rational target for anticancer therapy...
  41. ncbi FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
    Christian Fischer
    Department of Hepatology and Gastroenterology, Charite Universitatsmedizin, Berlin, Germany
    Nat Rev Cancer 8:942-56. 2008
    ..Hopefully, other agents with complementary mechanisms, such as those that target placental growth factor, will offer novel opportunities for improved treatment...
  42. ncbi Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us
    Lynn Hlatky
    Dana Farber Cancer Institute and the Department of Radiation Oncology, Harvard Medical School, Boston, MA 02115, USA
    J Natl Cancer Inst 94:883-93. 2002
  43. pmc Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
    Yuval Shaked
    Molecular and Cellular Biology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON M4N 3M5, Canada
    Cancer Cell 14:263-73. 2008
    ....
  44. ncbi A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration
    David S Boyer
    Retina Vitreous Associates Medical Group, 1127 Wilshire Boulevard, Los Angeles, CA 90017, USA
    Ophthalmology 116:1731-9. 2009
    ..To evaluate the safety and efficacy of intravitreal ranibizumab in a large population of subjects with neovascular age-related macular degeneration (AMD)...
  45. pmc Rapid vascular regrowth in tumors after reversal of VEGF inhibition
    Michael R Mancuso
    Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy, UCSF, San Francisco, California 94143 0452, USA
    J Clin Invest 116:2610-21. 2006
    ....
  46. pmc Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study
    Christopher G Willett
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 27:3020-6. 2009
    ..To assess the safety and efficacy of neoadjuvant bevacizumab with standard chemoradiotherapy in locally advanced rectal cancer and explore biomarkers for response...
  47. pmc Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
    Yuhui Huang
    Edwin L Steele Laboratory of Tumor Biology, Department of Radiation Oncology and Vaccine and Immunotherapy Center, Infectious Diseases Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 109:17561-6. 2012
    ....
  48. ncbi Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study
    Ezra E W Cohen
    Section of Hematology Oncology, Department of Medicine, University of Chicago Division of Biological Sciences, 5801 S Ellis, Chicago, IL 60637, USA
    J Clin Oncol 26:4708-13. 2008
    ..This multi-institutional study assessed the activity and safety of axitinib, an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 in patients with advanced thyroid cancer...
  49. ncbi Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
    Kathy Miller
    Indiana University Cancer Center, Indianapolis, USA
    N Engl J Med 357:2666-76. 2007
    ....
  50. pmc Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma
    Dan Huang
    Laboratory of Cancer Genetics, Laboratory of Computational Biology, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA
    Cancer Res 70:1063-71. 2010
    ..Our results reveal IL-8 as an important contributor to sunitinib resistance in ccRCC and a candidate therapeutic target to reverse acquired or intrinsic resistance to sunitinib in this malignancy...
  51. ncbi Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy
    Rafael Simo
    Diabetes Research Unit, Endocrinology Division, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Curr Diabetes Rev 2:71-98. 2006
    ..The main antiangiogenic factor is the pigment epithelium derived factor (PEDF) but the transforming growth factor beta (TGF-beta), thrombospondin (TSP) and somatostatin are also among the intraocullary synthesized antiangiogenic factors...
  52. ncbi Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study
    Robert A Burger
    University of California, Irvine Medical Center, Building 56, Room 264, 101 The City Dr, Orange, CA 92868, USA
    J Clin Oncol 25:5165-71. 2007
    ..We conducted a phase II trial to assess the efficacy and tolerability of single-agent bevacizumab, an anti-VEGF monoclonal antibody...
  53. ncbi Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases
    Frank Winkler
    E L Steele Laboratory for Tumor Biology, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Cancer Cell 6:553-63. 2004
    ..During the normalization window, but not before or after it, VEGFR2 blockade increases pericyte coverage of brain tumor vessels via upregulation of Ang1 and degrades their pathologically thick basement membrane via MMP activation...
  54. ncbi Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration
    Napoleone Ferrara
    Genentech, Inc, 1 DNA Way, South San Francisco, CA 94080, USA
    Retina 26:859-70. 2006
    ..Among these, ranibizumab is a high affinity recombinant Fab that neutralizes all isoforms of VEGF-A. The article briefly reviews the biology of VEGF and then focuses on the path that led to clinical development of ranibizumab...
  55. ncbi The multifaceted circulating endothelial cell in cancer: towards marker and target identification
    Francesco Bertolini
    Division of Hematology Oncology, Department of Medicine, European Institute of Oncology, 20141 Milan, Italy
    Nat Rev Cancer 6:835-45. 2006
    ....
  56. pmc Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization
    Dai Fukumura
    Edwin L Steele Laboratory, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, 100 Blossom Street Cox 7, Boston, MA 02114, USA
    Microvasc Res 74:72-84. 2007
    ..Combination of cytotoxic therapy and anti-angiogenic treatment during the vascular normalization exhibits synergistic effect...
  57. pmc Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2
    Jennifer L Spratlin
    FRCPC, Department of Medical Oncology, Cross Cancer Institute, 11560 University Ave, Edmonton, Alberta, Canada T5G 1Z2
    J Clin Oncol 28:780-7. 2010
    ....
  58. ncbi Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results
    Hope S Rugo
    University of California, San Francisco Comprehensive Cancer Center, USA
    J Clin Oncol 23:5474-83. 2005
    ....
  59. ncbi Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage
    Young Jun Koh
    Korea Advanced Institute of Science and Technology, Daejeon, Korea
    Cancer Cell 18:171-84. 2010
    ..Thus, simultaneous blockade of VEGF-A and angiopoietins with DAAP is an effective therapeutic strategy for blocking tumor angiogenesis, metastasis, and vascular leakage...
  60. ncbi Sunitinib: from rational design to clinical efficacy
    Laura Q M Chow
    Department of Medical Oncology, University of Colorado Health Sciences Center, Aurora, CO 80045, USA
    J Clin Oncol 25:884-96. 2007
    ....
  61. ncbi Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action
    Judah Folkman
    Children s Hospital Harvard Medical School, Cambridge, MA, USA
    Exp Cell Res 312:594-607. 2006
    The first angiogenesis inhibitors for cancer have now been approved by the F.D.A. in the U.S. and in 28 other countries, including China. The majority of these are monotherapies that block VEGF...
  62. ncbi Biomarkers to predict the clinical efficacy of bevacizumab in cancer
    Adrian M Jubb
    Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
    Lancet Oncol 11:1172-83. 2010
    ..Many questions relating to these and other surrogate biomarkers, however, remain unanswered and their clinical usefulness has yet to be proven...
  63. ncbi Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
    Brian I Rini
    Department of Solid Tumor Oncology and Urology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk R35, Cleveland, OH 44195, USA
    J Clin Oncol 26:3743-8. 2008
    ..To assess the safety and efficacy of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma (mRCC) and explore biomarkers for sunitinib response...
  64. ncbi Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
    Bernard Escudier
    Department of Medicine, Institut Gustave Roussy, Villejuif, France
    Lancet 370:2103-11. 2007
    ..Therefore, an investigation of the combination treatment of the humanised anti-VEGF monoclonal antibody bevacizumab with interferon alfa was warranted...
  65. pmc Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme
    Albert Lai
    David Geffen School of Medicine at UCLA, Reed Neurological Research Center, Los Angeles, CA 90095, USA
    J Clin Oncol 29:142-8. 2011
    ..The objectives were to determine the efficacy of this treatment combination and the associated toxicity...
  66. ncbi Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study
    David M Brown
    Retinal Consultants of Houston, Houston, Texas, USA
    Ophthalmology 118:1594-602. 2011
    ..Assess 12-month efficacy and safety of intraocular injections of 0.3 mg or 0.5 mg ranibizumab in patients with macular edema after branch retinal vein occlusion (BRVO)...
  67. ncbi Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma
    J Randolph Hecht
    David Geffen School of Medicine at University of California, Los Angeles, Santa Monica, CA 90404, USA
    J Clin Oncol 29:1997-2003. 2011
    ....
  68. ncbi Cancer prevention by targeting angiogenesis
    Adriana Albini
    IRCCS Multimedica, Science and Technology Pole, via Fantoli 16 15, Milan 20138, Italy adriana albini multimedica it
    Nat Rev Clin Oncol 9:498-509. 2012
    ....
  69. ncbi Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050)
    Karin Jennbacken
    Sahlgrenska Cancer Center, Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Box 425, 40530 Goteborg, Sweden
    Prostate 72:913-24. 2012
    ..Its mechanism of action is not fully elucidated, but previous studies show anti-angiogenic effects and strong interaction with the S100A9 protein...
  70. pmc Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema
    Michael J Elman
    Elman Retina Group, PA, Baltimore, Maryland, USA
    Ophthalmology 118:609-14. 2011
    ..5 mg ranibizumab or 4 mg triamcinolone combined with focal/grid laser compared with focal/grid laser alone for treatment of diabetic macular edema (DME)...
  71. ncbi Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial
    Jeffrey S Heier
    Ophthalmic Consultants of Boston, Boston, Massachusetts, USA
    Ophthalmology 119:802-9. 2012
    ..To assess long-term safety and efficacy of intraocular ranibizumab injections in patients with macular edema after retinal vein occlusion (RVO)...
  72. ncbi Tumor angiogenesis: past, present and the near future
    R S Kerbel
    Sunnybrook and Women s College Health Sciences Centre, Division of Cancer Biology Research, S 218 Research Building, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Carcinogenesis 21:505-15. 2000
    ..However, significant problems remain in the clinical application of angiogenesis inhibitors such as the need for surrogate markers to monitor the effects of such drugs when they do not cause tumor ..
  73. pmc Controlling escape from angiogenesis inhibitors
    Barbara Sennino
    the UCSF Helen Diller Family Comprehensive Cancer Center, Cardiovascular Research Institute and Department of Anatomy, University of California, San Francisco, San Francisco, California 94143 0452, USA
    Nat Rev Cancer 12:699-709. 2012
    ..New therapeutic approaches that target pathways that are involved in the escape mechanisms add the benefits of blocking tumour progression to those of slowing tumour growth by inhibiting angiogenesis...
  74. ncbi Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia
    Annamaria Rapisarda
    SAIC Frederick Inc, Frederick National Laboratory for Cancer Research, 1050 Boyles Street, Frederick, MD 21702, USA
    Nat Rev Clin Oncol 9:378-90. 2012
    ..As a potential remedy, a number of therapeutic approaches have been investigated that target the hypoxic tumour compartment to improve the clinical outcome of antiangiogenic therapy...
  75. ncbi Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study
    Ursula Schmidt-Erfurth
    Department of Ophthalmology, University of Vienna, Waehringer Guertel, Vienna, Austria
    Ophthalmology 118:831-9. 2011
    ..To demonstrate noninferiority of a quarterly treatment regimen to a monthly regimen of ranibizumab in patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD)...
  76. ncbi A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma
    Ashwatha Narayana
    Departments of Radiation Oncology, New York University Langone Medical Center, New York, New York 10016, USA
    J Neurosurg 116:341-5. 2012
    ..The authors conducted a prospective clinical trial to test the effectiveness of bevacizumab, an inhibitor of VEGF, in newly diagnosed GBM...
  77. ncbi Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients
    Toru Mukohara
    National Cancer Center Hospital East, Oncology Hematology, Kashiwa, Japan
    Cancer Sci 101:963-8. 2010
    ..Axitinib 5 mg twice-daily is the recommended starting dose for Japanese patients. This trial is registered with ClinicalTrials.gov, identifier NCT00447005...
  78. ncbi Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma
    Eric Van Cutsem
    Digestive Oncology Unit, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    J Clin Oncol 29:2004-10. 2011
    ..PTK787/ZK 222584 (PTK/ZK) is a novel oral angiogenesis inhibitor with therapeutic potential for the treatment of solid tumors...
  79. pmc Angiogenesis inhibitors: current strategies and future prospects
    Kristina M Cook
    Molecular Pharmacology Section, Medical Oncology Branch and Affiliates, National Cancer Institute, National Institutes of Health, 10 Center Drive, 9000 Rockville Pike, Bethesda, MD 20892, USA
    CA Cancer J Clin 60:222-43. 2010
    ..The following review describes key molecular mechanisms and novel therapies that are on the horizon for antiangiogenic tumor therapy...
  80. ncbi An overview of small-molecule inhibitors of VEGFR signaling
    S Percy Ivy
    Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA
    Nat Rev Clin Oncol 6:569-79. 2009
    ..The on-target effects seem to be mechanistically based and predicted by VEGFR inhibition. Small-molecule inhibitors of angiogenesis are active in a wide variety of malignancies and fill a unique niche for cancer therapeutics...
  81. ncbi Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy
    J F Arevalo
    Clinica Oftalmologica Centro Caracas, Edif Centro Caracas PH 1, Av Panteon, San Bernardino, Caracas 1010, Venezuela
    Br J Ophthalmol 92:213-6. 2008
    ....
  82. ncbi Mechanisms of resistance to antiangiogenesis therapy
    Faisal Azam
    University Department of Medical Oncology, Cancer and Haematology Centre, Level 2, Churchill Hospital, Oxford OX3 7LJ, United Kingdom
    Eur J Cancer 46:1323-32. 2010
    ..This article reviews current knowledge on resistance mechanisms and the therapeutic implications...
  83. ncbi Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3
    Dana D Hu-Lowe
    Department of Cancer Biology, PGRD La Jolla, Pfizer, Inc, San Diego, California 92121, USA
    Clin Cancer Res 14:7272-83. 2008
    ..We provide a comprehensive description of its in vitro characteristics and activities, in vivo antiangiogenesis, and antitumor efficacy and translational pharmacology data...
  84. ncbi The anti-angiogenic basis of metronomic chemotherapy
    Robert S Kerbel
    Molecular and Cellular Biology Research, Sunnybrook and Women s College Health Sciences Centre, S 217, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5, Canada
    Nat Rev Cancer 4:423-36. 2004
  85. ncbi Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis
    Shobha Rani Nalluri
    Division of Medical Oncology, Department of Medicine, Stony Brook University, Stony Brook, New York 11794, USA
    JAMA 300:2277-85. 2008
    ..Currently, the role of bevacizumab in venous thromboembolism is controversial...
  86. pmc A critical analysis of current in vitro and in vivo angiogenesis assays
    Carolyn A Staton
    Microcirculation Research Group, Academic Unit of Surgical Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, Sheffield, UK
    Int J Exp Pathol 90:195-221. 2009
    ..Finally, we briefly discuss the direction likely to be taken in future studies, which include the use of increasingly sophisticated imaging analysis systems for data acquisition...
  87. ncbi Integrins: the keys to unlocking angiogenesis
    Rita Silva
    Adhesion and Angiogenesis Group, Centre for Tumour Biology, Cancer Research UK Clinical Centre, Institute of Cancer, Barts and The London and Queen Mary s School of Medicine and Dentistry, John Vane Science Centre, Charterhouse Square, London UK
    Arterioscler Thromb Vasc Biol 28:1703-13. 2008
    ..Here we review the contribution of endothelial and mural cell integrins to angiogenesis and highlight their potential as antiangiogenesis targets...
  88. pmc Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
    C H Meyer
    Department of Ophthalmology, University of Bonn, Bonn, Germany
    Eye (Lond) 25:661-72. 2011
    ..In conclusion, overlapping yet distinct pharmacological properties of ranibizumab and bevacizumab indicate that safety or efficacy data from one cannot be extrapolated to the other...
  89. pmc Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors
    Dawid G Nowak
    Microvascular Research Laboratories, Bristol Heart Institute, Department of Physiology and Pharmacology, School of Veterinary Sciences, University of Bristol, Southwell Street, Bristol BS2 8EJ, UK
    J Cell Sci 121:3487-95. 2008
    ....
  90. pmc A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema
    Ingrid U Scott
    Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647, USA
    Ophthalmology 114:1860-7. 2007
    ..To provide data on the short-term effect of intravitreal bevacizumab for diabetic macular edema (DME)...
  91. pmc Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib
    Brian I Rini
    Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44195, USA
    J Natl Cancer Inst 103:763-73. 2011
    ..We evaluated the association of sunitinib-induced HTN with antitumor efficacy and HTN-associated adverse events in patients with metastatic renal cell carcinoma...
  92. ncbi Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors
    Roy S Herbst
    Premiere Oncology, California, 2020 Santa Monica Blvd, Suite 600, Santa Monica, CA 90404, USA
    J Clin Oncol 27:3557-65. 2009
    ..AMG 386 also appeared to impact tumor vascularity and showed antitumor activity in this patient population...
  93. pmc Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization
    Ruud P M Dings
    Department of Biochemistry, University of Minnesota, Minneapolis, USA
    Clin Cancer Res 13:3395-402. 2007
    ....
  94. ncbi Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
    Henk M W Verheul
    University Medical Center Utrecht, Heidelberglaan 100, 3584 CX, Utrecht, The Netherlands
    Nat Rev Cancer 7:475-85. 2007
    Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer...
  95. pmc Zebrafish bioassay-guided natural product discovery: isolation of angiogenesis inhibitors from East African medicinal plants
    Alexander D Crawford
    Department of Pharmaceutical Sciences, University of Leuven, Leuven, Belgium
    PLoS ONE 6:e14694. 2011
    ..These results suggest that the combination of zebrafish bioassays with analytical chromatography methods is an effective strategy for the rapid identification of bioactive natural products...
  96. ncbi Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema
    Masoud Soheilian
    Ophthalmology Department, Labbafinejad Medical Center, Shaheed Beheshti Medical University, Tehran, Iran
    Ophthalmology 116:1142-50. 2009
    ..To compare the results of intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal triamcinolone acetonide (IVT) versus macular laser photocoagulation (MPC) as a primary treatment of diabetic macular edema (DME)...
  97. ncbi VEGF-A: a critical regulator of blood vessel growth
    Napoleone Ferrara
    Genentech, Inc, San Francisco, CA 94080, USA
    Eur Cytokine Netw 20:158-63. 2009
    ..This article examines the molecular and biological characteristics of VEGF and also discusses preclinical and clinical studies with VEGF inhibitors and the lessons learned from these studies...
  98. ncbi Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study
    Lucio Crino
    Department of Oncology, Hospital Santa Maria della Misericordia, Sant Andrea delle Fratte, Perugia, Italy
    Lancet Oncol 11:733-40. 2010
    ..The SAiL (MO19390) study was undertaken to assess the safety and efficacy of first-line bevacizumab combined with standard chemotherapy regimens in clinical practice...
  99. ncbi ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration
    Stephen R Wedge
    Department of Cancer and Infection Research, AstraZeneca, Cheshire SK10 4TG, United Kingdom
    Cancer Res 62:4645-55. 2002
    ..4 cm(3) volume. ZD6474 is currently in Phase I clinical development as a once-daily oral therapy in patients with advanced cancer...
  100. pmc Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications
    Balazs Dome
    Department of Tumor Biology and Thoracic Oncology, National Koranyi Institute of Pulmonology, Budapest, Hungary
    Am J Pathol 170:1-15. 2007
    ..This review intends to integrate our recent knowledge in this field into a rational strategy that could be the basis for developing effective clinical modalities using antivascular therapy for cancer...
  101. ncbi Metronomic chemotherapy: new rationale for new directions
    Eddy Pasquier
    Children s Cancer Institute Australia, Lowy Cancer Research Centre, UNSW, Randwick, NSW 2031, Australia
    Nat Rev Clin Oncol 7:455-65. 2010
    ..Finally, we highlight the research efforts that need to be made to facilitate the optimal development of metronomic chemotherapy...

Research Grants65

  1. Neuropilin and semaphorin, anti-angiogenesis activities and mechanisms
    Michael Klagsbrun; Fiscal Year: 2009
    ..Recently, there has been a surge in the development of angiogenesis inhibitors, some of which are already FDA approved, e.g...
  2. Novel Angiogenesis Inhibitors Targeting the Anthrax Toxin Receptors
    MICHAEL SEAN ROGERS; Fiscal Year: 2012
    ..g. macular degeneration, diabetic retinopathy, retinopathy of prematurity, cancer, cardiovascular disease, arthritis, etc.). ..
  3. Patient Oriented Research Program in Neuro-oncology
    Vinay K Puduvalli; Fiscal Year: 2013
    ....
  4. Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent
    Ritu Aneja; Fiscal Year: 2009
    ....
  5. Optimizing localized therapy for primary liver cancer: a clinical trial and model
    REBECCA ANNE MIKSAD; Fiscal Year: 2013
    ..abstract_text> ..
  6. Dietary Supplement Selenium and HIF-1alpha Regulation in Cancer
    Sreenivasulu Chintala; Fiscal Year: 2010
    ..Successful completion of the studies proposed will establish the role of Se in inhibiting HIF-11 in cancer and other disease for a disease free maintenance of life across the life span of an individual. ..
  7. Interactions of the angiopoietin and PD-ECGF pathways in tumor angiogenesis
    Edward L Schwartz; Fiscal Year: 2013
    ..Recent clinical trials suggest that most advanced pancreatic exocrine carcinomas are refractory to angiogenesis inhibitors, and this may be due to the hypovascularity and other biological features of these tumors...
  8. Structure, Function and Inhibition of Human Methionine Aminopeptidases
    Jun O Liu; Fiscal Year: 2012
    ..hMetAP2 was identified as the target of the fumagillin family of angiogenesis inhibitors and it was subsequently demonstrated that activation of the p53 pathway is required for the inhibition of ..
  9. Anti-angiogenesis of HC-HA Covalent Complex and PTX3 Purified from Fetal Membrane
    Scheffer C G Tseng; Fiscal Year: 2011
    ..By including PTX3 to HC"HA, we may develop a new class of angiogenesis inhibitors for treating many diseases in and beyond ophthalmology where pathologic angiogenesis threatens our vision ..
  10. Image-guided combination therapy: noninvasive assessment of delivery and response
    Susanta K Sarkar; Fiscal Year: 2013
    ....
  11. Cutaneous Hemangiomas and Signal Transduction
    Jack L Arbiser; Fiscal Year: 2012
    ..Indeed, discoveries made during the prior funding cycle include small molecule angiogenesis inhibitors such as honokiol, solenopsin, carbazole, and triphenylmethanes...
  12. Combination Therapies for Cancer Treatment
    David J Waxman; Fiscal Year: 2013
    ..To date, however, the survival benefit of these angiogenesis inhibitors has been rather modest and efforts to improve activity by combination with conventional chemotherapeutic ..
  13. Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
    Donald W Kufe; Fiscal Year: 2013
    ..I, l-ll pharmacokinetic and pharmacodynamic clinical trials of investigational new cytotoxic agents, angiogenesis inhibitors, signal transduction/cell cycle inhibitors, differentiating agents and anti-cancer vaccines...
  14. Oncolytic HSV Therapy in Immunocompetent Sarcoma Models
    Timothy P Cripe; Fiscal Year: 2010
    ..Our results will guide the design of future clinical trials using these novel agents. ..
  15. Regulation of thrombospondin-1 expression by glucose
    Olga I Stenina; Fiscal Year: 2010
    ....
  16. Novel Targeted Anticancer Agents from Marine Cyanobacteria
    Hendrik Luesch; Fiscal Year: 2013
    ..Fourth, we will mechanistically characterize the identified selective agents to pinpoint the molecular changes induced in the cancer cell and to determine potential direct targets. ..
  17. Novel treatment strategies for enhancing sunitinib response in renal cell cancer
    Towia A Libermann; Fiscal Year: 2013
    ..Targeted therapies, particularly angiogenesis inhibitors such as sunitinib, have shown efficacy against metastatic RCC...
  18. Role of vascular mimicry in tumor escape from anti-angiogenic therapy
    JAMES MICHAEL DUNLEAVEY; Fiscal Year: 2013
    ..tumor cells express CD31, an endothelial selective marker, and lack the receptors typically targeted by angiogenesis inhibitors. Our lab specializes in studies of tumor endothelial cells (TEC)...
  19. Estrogen-related receptors in angiogenesis and cancer
    Jianrong Lu; Fiscal Year: 2013
    ..Recent advances have led to novel treatment modalities for cancer. Angiogenesis inhibitors are an important milestone in cancer therapeutics...
  20. Discovery and Investigation of Novel Angiogenesis Inhibitors Among Existing Drugs
    Jun O Liu; Fiscal Year: 2012
    ..The main objective of this application is to discover and develop new angiogenesis inhibitors from existing clinical drugs and to elucidate the molecular mechanisms of angiogenesis inhibition by two ..
  21. Phage Display with Two Genetically Incorporated Noncanonical Amino Acids
    Wenshe Liu; Fiscal Year: 2013
    ..The proposed research is significant because it will accelerate the current drug discovery progresses and contribute to fulfilling the NIH mission in promoting health and combating diseases. ..
  22. Evaluation of antiangiogenic role of EM011, a novel tubulin-binding agent
    Ritu Aneja; Fiscal Year: 2012
    ..abstract_text> ..
  23. Mechanism of KSHV-induced angiogenesis
    Shou Jiang Gao; Fiscal Year: 2012
    ..umbilical vein endothelial cells induces secretion of pro-angiogenic factors and represses secretion of angiogenesis inhibitors. Importantly, we have found that pro-angiogenic factors angiopoietin-2 (Ang-2), interleukin-6 (IL-6), and ..
  24. In vivo imaging and therapeutic targeting of hypoxic-niche associated with CSCs
    Keith M Stantz; Fiscal Year: 2012
    ..These goals are innovative and directly address an important clinical need, which can be extended to nearly all tumor types. ..
  25. Mechanism and therapeutic targeting of evasive resistance to antiangiogenic drugs
    Douglas Hanahan; Fiscal Year: 2012
    ..While much heralded, the arrival of angiogenesis inhibitors into the clinic, in particular ones targeting the VEGF signaling pathway, is not in general resulting in ..
  26. Role of TEMs in brain tumor dispersal
    Frank C Marini; Fiscal Year: 2013
    ..However, clinical practice reveals that cancer patients initially responding to angiogenesis inhibitors their tumors elicit an evasive resistance...
  27. Interaction of anti-angiogenic and cytotoxic therapies in colorectal cancer
    PETER J O'DWYER; Fiscal Year: 2013
    DESCRIPTION (provided by applicant): Angiogenesis inhibitors are the most successful of the targeted therapies tested to date...
  28. Systematic discovery of nonobvious human disease models by orthologous phenotypes
    Edward M Marcotte; Fiscal Year: 2012
    ..new angiogenesis genes &performing yeast-based compound screening to find new classes of anti-angiogenesis inhibitors, suitable as lead compounds for anti-cancer therapies...
  29. Wound Angiogenesis as a Biomarker for Tumor Angiogenesis
    Herbert I Hurwitz; Fiscal Year: 2010
    ..To exploit these similarities and understand the effects of angiogenesis inhibitors on wound healing, we have developed a safe and convenient dermal wound angiogenesis assay...
  30. Anti-VEGF in Tumors & Wounds: Efficacy vs Toxicity
    Herbert I Hurwitz; Fiscal Year: 2010
    ..To exploit these similarities and to understand the effects of angiogenesis inhibitors on wound healing, we have developed a safe and convenient clinical dermal wound angiogenesis assay...
  31. EXTENSION OF RADIOTHERAPY RESEARCH
    K Ang; Fiscal Year: 2009
    ..D. Anderson Cancer Center. The proposed work is anticipated to have a significant impact on radiation oncology with regard to both basic radiobiology and clinical applications. ..
  32. INTERACTIONS BETWEEN CYTOTOXIC AND ANTIANGIOGENIC DRUGS
    James M Gallo; Fiscal Year: 2013
    ..mechanisms calls for a systematic approach to define new treatment paradigms to alleviate resistance to angiogenesis inhibitors. The overall objective of the project is to provide a preclinical foundation to design multidrug ..
  33. Quantitative MRI Assessment of Tumor Hypoxia and Angiogenesis
    CHRISTOPHER CHAD QUARLES; Fiscal Year: 2010
    ..and treatment of cancer patients, especially considering recent advances in the clinical application of angiogenesis inhibitors and oxygen-enhancing agents...
  34. ENDOSTATIN RECEPTOR CDNA CLONING AND IONIC SIGNALING
    Seth Alper; Fiscal Year: 2001
    ..We have therefore taken this approach to the study of angiogenesis inhibitors, and have discovered that both angiostatin and endostatin trigger acute Ca2+ transients in primary ..
  35. The University of Texas M. D. Anderson Cancer Center SPORE in Melanoma
    Elizabeth A Grimm; Fiscal Year: 2013
    ..for development of a prognostic signature as well as a target therapy (#3);systemic deliver of angiogenesis inhibitors using nanoliposomal technology (#4);and genetic mechanisms of immunity and inflammation to generate an ..
  36. ANTI-ANGIOGENIC GENE THERAPY FOR RHEUMATOID ARTHRITIS
    Noriyuki Kasahara; Fiscal Year: 2001
    The purpose of these studies is to evaluate the therapeutic potential of the angiogenesis inhibitors thrombospondin-1, angiostatin, and endostatin, for gene therapy of rheumatoid arthritis...
  37. Development of a combination therapy for the treatment of prostate cancer
    FRANCIS MARKLAND; Fiscal Year: 2007
    ..These studies will advance the clinical potential of this novel anticancer protein. [unreadable] [unreadable] [unreadable]..
  38. Therapeutic Potential of A Novel Angiogenic Inhibitor
    James Ryan; Fiscal Year: 2003
    ..This study will use oxygen-induced retinopathy and streptozotocin (STZ)- induced diabetic rats as models. The effect of KBP injection on vascular permeability will be evaluated by the Evans Blue leakage method. ..
  39. Exploration and development of antiangiogenic peptides for breast cancer
    Aleksander S Popel; Fiscal Year: 2010
    ..It will also provide a better understanding of the role of several tissue proteins in maintaining healthy vascular balance and how this role may change in disease conditions. ..
  40. VEGF-dependent and - Independent Anti-angiogenic Therapy
    Calvin Kuo; Fiscal Year: 2006
    ..promising modality for the treatment of malignancies, although controlled comparisons between putative angiogenesis inhibitors has been lacking...
  41. Release of Angiogenic Inhibitors for Macular Edema
    Yan Feng; Fiscal Year: 2004
    ..The slow releasing polymers and delivery techniques can be applied to other peptide drugs in the treatment of ocular disorders. ..
  42. A New Therapy for Diabetic Macular Edema
    Jian Xing Ma; Fiscal Year: 2004
    ..This new treatment will use natural human peptides and will be less invasive. This new therapy, if successful, can prevent vision loss from macular edema in diabetic patients. ..
  43. A New Therapy for Diabetic Macular Edema
    Jian Xing Ma; Fiscal Year: 2007
    ..This new treatment will use natural human peptides and will be less invasive. This new therapy, if successful, can prevent vision loss from macular edema in diabetic patients. ..
  44. Angiogenesis: Advances in Basic Science and Therapeutic Applications
    JAMES WAVELL AIKEN; Fiscal Year: 2011
    ..In addition, several angiogenesis inhibitors have been approved by the FDA as therapy for cancer or intraocular neovascular disorders...
  45. Targeted Modulation of Angiogenesis by VEGFR Peptidomimetic Antagonists
    Renata Pasqualini; Fiscal Year: 2012
    ..phage display methods, and to apply these new agents as a forthcoming generation of safe and effective angiogenesis inhibitors. Our specific aims are: (i) to discover and develop new anti-angiogenic peptidomimetic compounds ..
  46. INHIBITION OF PROGESTIN-DEPENDENT ANGIOGENESIS IN BREAST CANCER
    CANDACE CARROLL; Fiscal Year: 2009
    ....
  47. ANGIOGENESIS INHIBITORS: A MECHANISM OF ACTION
    Erkki Ruoslahti; Fiscal Year: 2006
    ..We will also determine whether the angiogenesis inhibitors affect the incorporation of bone marrow-derived endothelial cell progenitors to colonize angiogenic sites...
  48. TUMOR PHYSIOLOGICAL EFFECTS OF ANGIOGENESIS INHIBITION
    William Lee; Fiscal Year: 2002
    b>Angiogenesis inhibitors are being tested as cancer therapeutics with the idea of controlling tumor growth by preventing expansion of their blood supply, but little is known about the intermediary mechanisms and processes involved...
  49. Regulation of angiogenic balance by thrombospondin-1.
    Olga Volpert; Fiscal Year: 2009
    ..These studies will yield new targets for therapeutic intervention using natural inhibitors. ..
  50. APPROACHES TO BRAIN TUMOR THERAPY
    Steven Brem; Fiscal Year: 2002
    ..Specifically, the Brain Tumor Research Laboratory will continue to develop angiogenesis inhibitors: two Phase II protocols using penicillamine for malignant gliomas are under review at the NABTT Central ..
  51. ANTI-ANGIOGENESIS GENE THERAPY FOR DE NOVO TUMORS
    Terry van Dyke; Fiscal Year: 2002
    ..Recently, two angiogenesis inhibitors (AngIs), angiostatin and endostatin, were isolated from human tumor xenografts in mice by the Folkman lab ..
  52. The Role of Vascular Maturation in Adipose Tissue Growth
    SUSAN DALLABRIDA; Fiscal Year: 2006
    ..earlier work showed that the supporting vasculature is uniquely plastic and susceptible to angiogenesis inhibitors. Mature vascular beds do not typically have these characteristics...
  53. The Role of SPARC in Neuroblastoma Angiogenesis
    Susan Cohn; Fiscal Year: 2007
    ..Schwann cells as well as differentiated NB tumor cells produce a spectrum of angiogenesis inhibitors including tissue inhibitor of metalloproteinase-2 (TIMP-2) and pigment epithelium-derived factor (PEDF)...
  54. A NEW ANTICANCER ANGOIGENESIS INHIBITOR FROM HUMAN URINE
    Hui Zhao; Fiscal Year: 2000
    ..Therefore, we propose that angiogenesis inhibitors purified from urine of cancer patients could have a potent antineoplastic activity in humans...
  55. TOTAL SYNTHESIS OF BIOACTIVE NATURAL PRODUCTS
    Richmond Sarpong; Fiscal Year: 2012
    ..The cortistatins are potent angiogenesis inhibitors and should find use in combating tumor cell metastasis...
  56. INHIBITION OF ANGIOGENESIS-- PROTEINS BINDING TO TSP2
    Kiflai Bein; Fiscal Year: 2004
    ..It is hoped that the studies will serve as the basis for designing more potent antiangiogenic reagents. ..
  57. NEW CLINICAL BIOMARKER FOR CANCER--WOUND ANGIOGENESIS
    Herbert Hurwitz; Fiscal Year: 2005
    Tumor angiogenesis has recently been shown to play essential role in tumor growth and metastases. Angiogenesis inhibitors are a promising new class of drugs with great potential for the treatment of human cancers, as well as other ..
  58. Cocktail of Angiogenic Inhibitors for the Treatment of Diabetic Macular Edema
    Gennadiy Moiseyev; Fiscal Year: 2006
    ..This approach could open a new way to treat DME using cocktails of drugs with different molecular mechanisms. [unreadable] [unreadable]..
  59. Qualifying effectiveness of angiogenic inhibitors
    Philip Hahnfeldt; Fiscal Year: 2004
    ..Quantitative modeling is proposed as a relatively inexpensive and rapid way to help bridge the gap between experiments and clinical implementations for dose, dose-timing, and inhibitor combinations. ..
  60. Enhancing Photodynamic Therapy for Treating Kaposi's Sarcoma
    Charles Gomer; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  61. Development of a New Antiangiogenic Tumor Blocker SBD 1
    Krzysztof Bojanowski; Fiscal Year: 2002
    ..The results of Phase I/II clinical trials completed so far with several angiogenesis inhibitors validate the concept of tumor angiogenesis as effective target for anti-cancer therapy...
  62. Role of Vessel Maturity in Antiangiogenic Drug Efficacy
    Maria Rupnick; Fiscal Year: 2005
    Tumor growth is angiogenesis dependent yet tumor responses to angiogenesis inhibitors vary unpredictably. We propose that a dominant variable governing a tumor's response to these drugs is the maturation state of its vasculature...
  63. Angiocidal Effect of Cyclosporine in Cancer Therapy
    Dilip Kittur; Fiscal Year: 2006
    ..Our studies have the potential of discovering a novel, angiocidal effect of a commonly used drug. If successful, these studies will be translated expeditiously into clinical trials for the treatment of cancer. ..
  64. Quantitative MRI Assessment of Tumor Hypoxia and Angiogenesis
    CHRISTOPHER QUARLES; Fiscal Year: 2007
    ..and treatment of cancer patients, especially considering recent advances in the clinical application of angiogenesis inhibitors and oxygen-enhancing agents...
  65. MATRIXINS AND THEIR INHIBITORS IN ANGIOGENESIS
    QING XIANG SANG; Fiscal Year: 2002
    ..b>Angiogenesis inhibitors may become one of the most promising types of drugs for starving tumor cells and preventing the spread of ..